REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.75
-0.11 (-1.34%)
Jan 23, 2025, 12:29 PM EST - Market open
REGENXBIO Revenue
REGENXBIO had revenue of $24.20M in the quarter ending September 30, 2024, a decrease of -16.31%. This brings the company's revenue in the last twelve months to $84.33M, down -15.14% year-over-year. In the year 2023, REGENXBIO had annual revenue of $90.24M, down -19.94%.
Revenue (ttm)
$84.33M
Revenue Growth
-15.14%
P/S Ratio
4.45
Revenue / Employee
$245,137
Employees
344
Market Cap
383.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
RGNX News
- 7 days ago - Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 - Seeking Alpha
- 7 days ago - Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again - Seeking Alpha
- 9 days ago - REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases - PRNewsWire
- 10 days ago - AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program - PRNewsWire
- 6 weeks ago - Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 - PRNewsWire
- 2 months ago - REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PRNewsWire
- 2 months ago - REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 - PRNewsWire
- 2 months ago - REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript - Seeking Alpha